Cargando…

Structural basis of human LRG1 recognition by Magacizumab, a humanized monoclonal antibody with therapeutic potential

The formation of new dysfunctional blood vessels is a crucial stage in the development of various conditions such as macular degeneration, diabetes, cardiovascular disease, neurological disease and inflammatory disorders, as well as during tumor growth, eventually contributing to metastasis. An impo...

Descripción completa

Detalles Bibliográficos
Autores principales: Gutiérrez-Fernández, Javier, Javaid, Faiza, De Rossi, Giulia, Chudasama, Vijay, Greenwood, John, Moss, Stephen E., Luecke, Hartmut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Union of Crystallography 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159282/
https://www.ncbi.nlm.nih.gov/pubmed/35647920
http://dx.doi.org/10.1107/S2059798322004132
_version_ 1784719023314829312
author Gutiérrez-Fernández, Javier
Javaid, Faiza
De Rossi, Giulia
Chudasama, Vijay
Greenwood, John
Moss, Stephen E.
Luecke, Hartmut
author_facet Gutiérrez-Fernández, Javier
Javaid, Faiza
De Rossi, Giulia
Chudasama, Vijay
Greenwood, John
Moss, Stephen E.
Luecke, Hartmut
author_sort Gutiérrez-Fernández, Javier
collection PubMed
description The formation of new dysfunctional blood vessels is a crucial stage in the development of various conditions such as macular degeneration, diabetes, cardiovascular disease, neurological disease and inflammatory disorders, as well as during tumor growth, eventually contributing to metastasis. An important factor involved in pathogenic angiogenesis is leucine-rich α-2-glycoprotein 1 (LRG1), the antibody blockade of which has been shown to lead to a reduction in both choroidal neovascularization and tumor growth in mouse models. In this work, the structural interactions between the LRG1 epitope and the Fab fragment of Magacizumab, a humanized function-blocking IgG4 against LRG1, are analysed, determining its specific binding mode and the key residues involved in LRG1 recognition. Based on these structural findings, a series of mutations are suggested that could be introduced into Magacizumab to increase its affinity for LRG1, as well as a model of the entire Fab–LRG1 complex that could enlighten new strategies to enhance affinity, consequently leading towards an even more efficient therapeutic.
format Online
Article
Text
id pubmed-9159282
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher International Union of Crystallography
record_format MEDLINE/PubMed
spelling pubmed-91592822022-06-17 Structural basis of human LRG1 recognition by Magacizumab, a humanized monoclonal antibody with therapeutic potential Gutiérrez-Fernández, Javier Javaid, Faiza De Rossi, Giulia Chudasama, Vijay Greenwood, John Moss, Stephen E. Luecke, Hartmut Acta Crystallogr D Struct Biol Research Papers The formation of new dysfunctional blood vessels is a crucial stage in the development of various conditions such as macular degeneration, diabetes, cardiovascular disease, neurological disease and inflammatory disorders, as well as during tumor growth, eventually contributing to metastasis. An important factor involved in pathogenic angiogenesis is leucine-rich α-2-glycoprotein 1 (LRG1), the antibody blockade of which has been shown to lead to a reduction in both choroidal neovascularization and tumor growth in mouse models. In this work, the structural interactions between the LRG1 epitope and the Fab fragment of Magacizumab, a humanized function-blocking IgG4 against LRG1, are analysed, determining its specific binding mode and the key residues involved in LRG1 recognition. Based on these structural findings, a series of mutations are suggested that could be introduced into Magacizumab to increase its affinity for LRG1, as well as a model of the entire Fab–LRG1 complex that could enlighten new strategies to enhance affinity, consequently leading towards an even more efficient therapeutic. International Union of Crystallography 2022-05-09 /pmc/articles/PMC9159282/ /pubmed/35647920 http://dx.doi.org/10.1107/S2059798322004132 Text en © Javier Gutiérrez-Fernández et al. 2022 https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.
spellingShingle Research Papers
Gutiérrez-Fernández, Javier
Javaid, Faiza
De Rossi, Giulia
Chudasama, Vijay
Greenwood, John
Moss, Stephen E.
Luecke, Hartmut
Structural basis of human LRG1 recognition by Magacizumab, a humanized monoclonal antibody with therapeutic potential
title Structural basis of human LRG1 recognition by Magacizumab, a humanized monoclonal antibody with therapeutic potential
title_full Structural basis of human LRG1 recognition by Magacizumab, a humanized monoclonal antibody with therapeutic potential
title_fullStr Structural basis of human LRG1 recognition by Magacizumab, a humanized monoclonal antibody with therapeutic potential
title_full_unstemmed Structural basis of human LRG1 recognition by Magacizumab, a humanized monoclonal antibody with therapeutic potential
title_short Structural basis of human LRG1 recognition by Magacizumab, a humanized monoclonal antibody with therapeutic potential
title_sort structural basis of human lrg1 recognition by magacizumab, a humanized monoclonal antibody with therapeutic potential
topic Research Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159282/
https://www.ncbi.nlm.nih.gov/pubmed/35647920
http://dx.doi.org/10.1107/S2059798322004132
work_keys_str_mv AT gutierrezfernandezjavier structuralbasisofhumanlrg1recognitionbymagacizumabahumanizedmonoclonalantibodywiththerapeuticpotential
AT javaidfaiza structuralbasisofhumanlrg1recognitionbymagacizumabahumanizedmonoclonalantibodywiththerapeuticpotential
AT derossigiulia structuralbasisofhumanlrg1recognitionbymagacizumabahumanizedmonoclonalantibodywiththerapeuticpotential
AT chudasamavijay structuralbasisofhumanlrg1recognitionbymagacizumabahumanizedmonoclonalantibodywiththerapeuticpotential
AT greenwoodjohn structuralbasisofhumanlrg1recognitionbymagacizumabahumanizedmonoclonalantibodywiththerapeuticpotential
AT mossstephene structuralbasisofhumanlrg1recognitionbymagacizumabahumanizedmonoclonalantibodywiththerapeuticpotential
AT lueckehartmut structuralbasisofhumanlrg1recognitionbymagacizumabahumanizedmonoclonalantibodywiththerapeuticpotential